{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pelvic-inflammatory-disease/prescribing-information/ofloxacin/","result":{"pageContext":{"chapter":{"id":"f5753d3f-d2cb-58c0-a3ba-9ea9ad6651ba","slug":"ofloxacin","fullItemName":"Ofloxacin","depth":2,"htmlHeader":"<!-- begin field 482b308b-aaf1-459b-8646-9ae49cd9e2b0 --><h2>Ofloxacin</h2><!-- end field 482b308b-aaf1-459b-8646-9ae49cd9e2b0 -->","summary":"","htmlStringContent":"<!-- begin item a3b8864f-be0b-492f-bd57-911b26de6e8d --><!-- end item a3b8864f-be0b-492f-bd57-911b26de6e8d -->","topic":{"id":"9f0279a4-2834-5e5a-bcac-8bf82aa33bc3","topicId":"c3fb3eae-a416-4305-9bb7-f8c4a28827e3","topicName":"Pelvic inflammatory disease","slug":"pelvic-inflammatory-disease","lastRevised":"Last revised in June 2019","chapters":[{"id":"5f211e92-2994-512e-b182-200dcee7cfe5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d99b28e-147a-50d9-b809-b2997de385cd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"edca47ac-ad32-5cdc-b5b0-044c08354023","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61747f80-342b-5eee-9f57-5585e2e266a1","slug":"changes","fullItemName":"Changes"},{"id":"34323845-1d0f-5dd2-9d12-aa4195ea061a","slug":"update","fullItemName":"Update"}]},{"id":"41aa50e1-c3d6-5af5-8d64-bf56566bcf4a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5485b6d3-ad41-5a4f-8068-3927541fc840","slug":"goals","fullItemName":"Goals"},{"id":"8e512ac7-b08d-5db9-b36c-0b6bf6adeab6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"16ee94a8-ef4e-5d73-9aab-3a7ad56481d0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"00ebd775-876e-52d3-8917-e865f1ca24ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00b18462-2317-5fa1-964d-480008f24d93","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a76f3e2f-4836-5bfb-8b3d-65126afcd379","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b5957fa8-3b35-540f-93d4-a16fe133bcd7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ffd6d91-45b2-5f09-8a72-1269c1cf4194","slug":"definition","fullItemName":"Definition"},{"id":"8d2eecb8-da49-56f0-b0f3-512e1ef7da78","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cd56fa88-472b-5053-8750-7288cff96a45","slug":"incidence","fullItemName":"Incidence"},{"id":"eae17c05-1a5f-5d75-be7c-b0e30fbc5151","slug":"complications","fullItemName":"Complications"}]},{"id":"13e64b0f-f012-5f38-978c-906828fd01c0","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6bef4b1a-5873-5e3c-a07f-a72df2163883","slug":"assessment","fullItemName":"Assessment"},{"id":"44e7ae24-ecb6-5611-a376-e300900a9915","slug":"investigations","fullItemName":"Investigations"},{"id":"f2d53656-5ddd-5cac-a2f0-5155e3e4816f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"04b9a20a-4646-577d-9db4-a82fad1f1122","fullItemName":"Management","slug":"management","subChapters":[{"id":"db64e69d-0dae-56cc-ac8c-111a4ae832f9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b38292-e76f-5f9e-b08f-9038f7a1e33c","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"33b4bf00-1e15-50d8-ae8e-cae48e64e869","slug":"ceftriaxone","fullItemName":"Ceftriaxone"},{"id":"07bec723-0e9e-5a18-9e33-37a6b08715b1","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"407d577d-6898-50ed-a49b-95ad0651ada7","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"631d3af6-f8a7-581f-9d98-a24412ab54f1","slug":"moxifloxacin","fullItemName":"Moxifloxacin"},{"id":"f5753d3f-d2cb-58c0-a3ba-9ea9ad6651ba","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"f7cbd9f8-3abb-50db-95c5-bb3b61731818","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b504e72-502e-54b1-8c90-a7bc3421bd9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c908da70-e8da-577d-aa14-2a477f0bc1cf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"07e835ee-992a-5310-a2e1-6c64c3dcf57f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"81326348-513f-5842-87bb-414706046cb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0f235ae8-132c-5727-bb43-da1eaf2b8a7d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0ba9a54-ce24-5b78-a3fa-c48701375f1c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8c22c848-92a6-5535-b584-48002acef06e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"99a5e1d6-22b2-537d-8972-529cd8d95146","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field d5dfdfb6-9a3d-4f05-98aa-a936010c9b0c --><h3>What are the contraindications and cautions?</h3><!-- end field d5dfdfb6-9a3d-4f05-98aa-a936010c9b0c -->","summary":"","htmlStringContent":"<!-- begin item 386835b7-02b1-4031-ac3e-a936010c9a80 --><!-- begin field 0001faaf-39fe-4fc7-bd74-a936010c9b0c --><ul><li><strong>Do not prescribe ofloxacin in people:</strong><ul><li>With glucose-6-phosphate dehydrogenase deficiency.</li><li>With a history of tendon disorders related to fluoroquinolone administration, or who have previously had serious adverse reactions with a quinolone or fluoroquinolone antibiotic.</li><li>Taking a corticosteroid — coadministration could exacerbate fluoroquinolone-induced tendonitis and tendon rupture.</li></ul></li><li><strong>Prescribe ofloxacin with caution in people with:</strong><ul><li>Aortic aneurysm and/or aortic dissection, a family history of aneurysm disease, or with risk factors or conditions predisposing for aortic aneurysm and dissection (for example, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, hypertension, known atherosclerosis).</li><li>Diabetes mellitus — may affect blood glucose. Blood glucose should be monitored closely.</li><li>A history of tendonitis — quinolones can very rarely cause tendon damage, and the risk of tendon rupture is increased by co-administration of corticosteroid.</li><li>Impaired liver function — liver damage can occur. </li><li>Conditions which predispose to QT interval prolongation:<ul><li>Congenital long QT syndrome.</li><li>Conccurrent use of drugs that are known to prolong the QT interval (for example Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</li><li>Uncorrected electrolyte imbalance (for example hypokalaemia, or hypomagnesaemia).</li><li>Cardiac disease (for example, heart failure, myocardial infarction, or bradycardia).</li><li>Electrolyte disturbances.</li></ul></li><li>History of a psychotic disorder — there have been reports of suicidal thoughts or self-endangering behaviour after use quinolones. </li><li>Myasthenia gravis — symptoms can be exacerbated.</li></ul></li><li>Also prescribe with caution in people aged over 60 years, people with renal impairment or solid-organ transplants, as they are at a higher risk of tendon injury.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">MHRA, 2019</a>]</p><!-- end field 0001faaf-39fe-4fc7-bd74-a936010c9b0c --><!-- end item 386835b7-02b1-4031-ac3e-a936010c9a80 -->","subChapters":[]},{"id":"59c126e0-b951-5a2c-aeaa-7eaf0f384048","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 89af567a-497e-4c9c-a358-a936010cbf0d --><h3>What are the adverse effects?</h3><!-- end field 89af567a-497e-4c9c-a358-a936010cbf0d -->","summary":"","htmlStringContent":"<!-- begin item a70c16de-204a-46d6-92b6-a936010cbe5a --><!-- begin field eb273f09-5763-4ea0-83f7-a936010cbf0d --><ul><li><strong>Cardiovascular system</strong> — tachycardia (rarely); ventricular arrhythmias, torsades de pointes, QT interval prolongation (frequency unknown).<ul><li>There is an increased risk of aortic aneurysm and dissection with fluoroquinolones, particularly in the older population. Fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in people with positive family history of aneurysm disease, or in people diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (for example, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet’s disease, hypertension, known atherosclerosis).</li></ul></li><li><strong>Gastrointestinal </strong>— diarrhoea, nausea, vomiting, abdominal pains (uncommon).<ul><li><strong>Very rarely</strong>: pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Musculoskeletal </strong>— tendonitis (rare).<ul><li><strong>Very rarely:</strong> arthralgia, myalgia, tendon rupture — this may occur within 48 hours of starting treatment, or months after stopping. Risk of tendon rupture is increased by co-administration of corticosteroids and in people aged over 60 years. If tendonitis is suspected, ciprofloxacin should be discontinued immediately.</li></ul></li><li><strong>Nervous system</strong> — headache, dizziness (uncommon),<ul><li><strong>Rarely</strong>: sleep disorders, taste disorders, tremor, vertigo, lowering of the seizure threshold – this may trigger seizures. </li></ul></li><li><strong>Psychiatric</strong> — agitation, sleep disorder, insomnia (uncommon).<ul><li><strong>Rarely</strong>: confusion, anxiety, depression, nightmares.</li></ul></li><li><strong>Skin</strong> — rash, pruritus (uncommon)<ul><li><strong>Rarely: </strong>Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis anaphylaxis, drug rash with eosinophilia, systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP).</li></ul></li><li><strong>Other adverse effects include: </strong><ul><li>Anaphylaxis.</li><li>Dyspnoea, bronchospasm.</li><li>Hepatic impairment, hepatitis.</li><li>Renal impairment.</li><li>Tachycardia.</li><li>Tinnitus.</li><li>Visual disturbances.</li></ul></li><li><strong>NOTE: </strong>fluoroquinolones can very rarely cause long-lasting (up to months or years), disabling, and potentially irreversible side effects, sometimes affecting multiple systems, organ classes, and senses. People should be advised to stop treatment at the first signs of a serious adverse reaction, such as tendonitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy, and central nervous system effects, and to contact their doctor immediately for further advice.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">MHRA, 2019</a>]</p><!-- end field eb273f09-5763-4ea0-83f7-a936010cbf0d --><!-- end item a70c16de-204a-46d6-92b6-a936010cbe5a -->","subChapters":[]},{"id":"2cbe2d04-87ff-51de-a4ce-dd39dac163f8","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 3c07fd6b-313c-4e05-a372-a936010cd892 --><h3>What are the drug interactions?</h3><!-- end field 3c07fd6b-313c-4e05-a372-a936010cd892 -->","summary":"","htmlStringContent":"<!-- begin item 0155c45e-ce8d-429d-b30e-a936010cd801 --><!-- begin field 425c05ac-b58d-4950-b1dc-a936010cd892 --><ul><li><strong>Antacids (containing aluminium, calcium, or magnesium) and other medications containing iron or zinc </strong>— these may reduce the absorption of ofloxacin if taken concurrently.<ul><li>Ofloxacin should be taken at least 2 hours before these preparations, and not less than 4 to 6 hours after them.</li></ul></li><li><strong>Corticosteroids</strong> — the risk of tendonitis and tendon rupture is increased in people taking a fluoroquinolone and a corticosteroid. The MHRA advises that concurrent should be avoided. </li><li><strong>Ergometrine </strong>— levels may be increased, leading to ergotism. Concurrent use is contraindicated. </li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— possible increased risk of seizures when quinolones are given with NSAIDs. Avoid concurrent use in people with epilepsy or people predisposed to seizures, or monitor them very closely.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of ofloxacin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Strontium ranelate </strong>— the absorption of quinolones is reduced by strontium ranelate so they should not be given together.</li><li><strong>Theophylline </strong>— ciprofloxacin increases the plasma concentration of theophylline, leading to possible increased risk of convulsions. There is the possibility of a similar effect with ofloxacin. Monitor theophylline concentration closely.</li><li><strong>Warfarin </strong>— rarely, ofloxacin may enhance the anticoagulant effect, increasing the risk of bleeding. Monitor the international normalised ratio (INR) within 3 to 5 days of starting ofloxacin, frequently during and shortly after administration.</li><li><strong>Zolmitriptan </strong>— quinolones increase the plasma concentration of zolmitriptan by inhibiting its metabolism. Manufacturer recommends a maximum dose of 5 mg in 24 hours in people taking a quinolone.</li><li><strong>Drugs that prolong the QT interval </strong>(such as Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, and antipsychotics) — very rare cases of QT interval prolongation have been reported in people taking quinolones and they should therefore be prescribed with caution alongside drugs known to prolong the QT interval.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">MHRA, 2019</a>]</p><!-- end field 425c05ac-b58d-4950-b1dc-a936010cd892 --><!-- end item 0155c45e-ce8d-429d-b30e-a936010cd801 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}